I am still thinking/hoping AMGN will be topic of many posts in this forum...

"Still, there are two solid reasons to consider buying this blue chip biotech stock right now. First up, Amgen's recent acquisition of the anti-inflammatory medicine Otezla is expected to immediately boost earnings and quarterly sales. The company should, in fact, return to top-line growth by next year. Second, Amgen has one of the largest cash positions within the entire space. So there's a good chance that the biotech will pursue more bolt-on acquisitions in order to accelerate its return to form. "